NCT02142803 - TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 20, 2014

Primary Completion Date

December 31, 2020

Study Completion Date

October 16, 2025

Conditions

Adult GlioblastomaEndometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Uterine Corpus NeoplasmRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaSolid NeoplasmStage IIIA Fallopian Tube Cancer AJCC v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIB Primary Peritoneal Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Stage IIIC Primary Peritoneal Cancer AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7

Interventions

BIOLOGICAL

Bevacizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Sapanisertib

Given PO

Trial Locations (3)

43210

Ohio State University Comprehensive Cancer Center, Columbus

02215

Dana-Farber Cancer Institute, Boston

02129

Massachusetts General Hospital, Charlestown

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH